IMPORTANCE Persistent, viscous middle ear effusion in pediatric otitis media (OM) contributes to increased likelihood of anesthesia and surgery, conductive hearing loss, and subsequent developmental delays. Biomarkers of effusion viscosity and hearing loss have not yet been identified despite the potential that such markers hold for targeted therapy and screening.
O titis media (OM) is the most common diagnosis in pediatric patients who visit physicians for illness in the United States and is responsible for approximately $5 billion in US health care expenditures annually. 1 Although the development of otitis media with effusion (OME) represents only a subset of patients affected by OM, it can lead to conductive hearing loss as a result of persisting OME and subsequent developmental delays. 2, 3 Such effusions are characterized by persistent, often viscous middle ear effusions and an increased likelihood of anesthesia and surgery. [2] [3] [4] For individuals who represent First Peoples (such as Native Americans, Australian Aboriginals, North American Eskimos, and Greenlanders), chronic OME and associated complications represent an even greater difficulty because of its incidence and severity in this population. 5 Therefore, OM represents an important pediatric health care problem around the world for which additional understanding of its underlying molecular mechanisms and novel solutions are needed, particularly for specific patient populations, such as those with chronic disease, developmental delays, economic or societal disadvantages, or other health care disparities. 6 To address the potential solutions for subpopulations, it is imperative that targeted solutions using a personalized genomic approach are explored. This article. to our knowledge, represents the first of its kind to examine the association of genetic expression to OM disease metrics in a group of patients chronically affected by OME and requiring surgery. Secreted, oligomeric, or gel-forming mucins (GFMs) are the primary constituent of middle ear effusion and are largely responsible for its viscoelastic properties. 7 These high-molecularweight proteins contain multiple serine-and threonine-rich mucin-like domains that are extensively glycosylated. Glycosylation contributes as much as 80% of the weight of the molecule and causes it to become stiff and voluminous, resulting in characteristic space-filling or gel-making properties. Entanglement of long mucin oligomers is considered to be the primary mechanism for mucous gel formation. Therefore, the size, concentration, and chemical nature of the mucins are important factors for determining the properties of effusion and its propensity for clearance. The GFMs expressed in the inflamed middle ear include mucin 2 (MUC2), mucin 5AC (MUC5AC), and mucin 5B (MUC5B). 8 Expression of these mucins during OME is triggered by bacterial infection and proinflammatory cytokines. [9] [10] [11] [12] [13] Although mucins play a key role in the innate immune response by entrapping foreign particles and pathogens and facilitating their clearance, mucin hypersecretion alters mucous gel properties, impedes effusion clearance, and is a pathologic feature of airway diseases, including OM. 4, 7 In addition to mucin expression, availability of water on the epithelial surface also significantly affects secreted mucin hydration and rheologic properties of the mucous gel. Aquaporins are integral membrane proteins that play a significant role in local water homeostasis by serving as selective pores for the rapid movement of water across diverse cell membranes. Aquaporin subtypes are expressed with regionspecific localization in the middle ear, where they may be responsible for maintaining the fluid-free middle ear cavity or accumulation of effusion.
14 Levels of aquaporins were elevated in an animal model of secretory OM and found to be 1 of the 2 major groups of homeostasis genes affected and in a mouse model of acute OM. 15, 16 Recent research indicates that a specific aquaporin, aquaporin 5 (AQP5), also regulates GFM expression in airway cells via epidermal growth factor receptor signaling, 17, 18 presenting a novel mechanism whereby aquaporin expression may influence middle ear effusion viscosity by altering its mucin composition. The association among GFM and AQP5 (OMIM 600442) expression, inflammation, middle ear effusion viscosity, and hearing loss has not, to our knowledge, been previously investigated. In this study, we assessed these associations in a pediatric population with OME undergoing tympanostomy tube (TT) placement relative to an OM-free control population.
Methods

Study Participants
Study design was reviewed by epidemiologic and biostatistical consultants before initiation of the study, with determination of group sizes informed by previous observational studies of patients with OM and control individuals. 19, 20 The number of controls was limited to that deemed necessary by power analysis in keeping with the best interest of patients; analysis methods accounted for any imbalance in population size, and resultant effects were reflected in the CIs. The study followed a clinical course design wherein the OME population was composed of referrals treated in a routine practice setting to most accurately reflect and inform clinical practice. Findings In this case-control study of 24 patients with otitis media with effusion and 7 control individuals, mucin 5B and aquaporin 5 gene expression were associated with effusion viscosity and mucin 5B with middle ear epithelial thickness and hearing loss.
Meaning Further study is warranted to investigate whether mucin 5B-targeted therapy may reduce effusion viscosity and ameliorate hearing loss, a serious consequence of otitis media with effusion.
implantation from February 1 through October 31, 2014, as a control population; the difference in age bracket was attributable to an expectation of mostly very young patient enrollees with cochlear implants. During the study period, consecutive patients who met the inclusion criteria were offered enrollment in the study. Patients considered in this study presented with OME, defined as 3 or more months of persisting middle ear effusion, to the pediatric otolaryngology clinic after referral from their primary physician with a history of persisting middle ear infections and middle ear fluid. Strict criteria were used in considering patients with OME for study inclusion: effusion that persisted for more than 3 months and substantive hearing or developmental concerns for more than 6 months with less severe hearing or developmental concerns. Specifically, all patients with OME considered in this study had unilateral or bilateral middle ear fluid at the time of their clinic evaluation and met surgical criteria for TT placement, including persisting middle ear fluid with meaningful hearing loss (>20 dB bilaterally), persisting recurrent infections despite hearing thresholds that were better than 20 dB, or associated speech delay and persisting OME despite hearing levels better than 20 dB. Exclusion criteria included 1 or more episodes of OM in the previous 12 months; history of immunologic, intrinsic, or pharmacologic abnormality; anatomical or physiologic defect of the ear; syndrome associated with OM (ie, Down syndrome, cleft palate); chronic mastoiditis; and history of cholesteatoma. Exclusion criteria for cochlear implantation controls matched the aforementioned criteria. Written informed consent was obtained before study enrollment and surgery. All data were deidentified.
For patients with OME, after performance of the myringotomy incision, fluid in the middle ear space was collected using Juhn Tym Tap middle ear fluid aspirator or collectors; for extremely thick, mucoid effusions, nonbacteriostatic saline was used to assist suction; if no effusion was present, no sample was collected. A surgeon (R.H.C., M.E.M., J.E.K.) noted the effusion viscosity at the time of collection using a ranking system (0, absent; 1, thin serous; 2, thick serous; 3, mucoid; 4, thick mucoid; 5, extremely thick mucoid resistant to 7F suctioning). Two to 3 small (<1-mm) biopsy specimens were taken from the middle ear with a cup forceps near the eustachian tube orifice (anterior-inferior promontory), and a TT was placed according to routine care. From each patient, one specimen was placed in RNAlater (Thermo Fisher Scientific) and the other in Hank's buffered saline solution (HBSS; Thermo Fisher Scientific) before immediate transport to the research laboratory. Samples in RNALater were stored at −80°C before RNA extraction. Samples in HBSS were immediately embedded for cryosectioning as described in the Analysis of Middle Ear Epithelial Thickness and Neutrophil Infiltration subsection of Methods. Mucosal biopsy specimens were obtained from a similar location of the middle ear of patients with cochlear implants during cochlear implantation. From each patient, one specimen was placed in RNAlater and the other in HBSS (specimens from Children's Hospital of Wisconsin, Milwaukee) or 10% formalin (specimens from Sick Kids Hospital in Toronto, Ontario, Canada). Samples in RNALater were stored at −80°C before RNA extraction. Samples in HBSS were immediately embedded for cryosectioning, and samples in formalin were stored at 4°C before embedding for cryosectioning as described in the Analysis of Middle Ear Epithelial Thickness and Neutrophil Infiltration subsection of Methods.
Audiometry tests with an auditory threshold assessment (expressed in decibels) were performed for all patients with OME in the study according to routine care by an experienced audiologist within 21 days before TT insertion. Pure-tone audiometry was performed for patients older than 3 years: air conduction and bone conduction thresholds were measured at frequencies of 500, 1000, 2000, and 4000 Hz, and the mean and air-bone gap were noted. In younger children unable to be assessed by pure-tone audiometry, sound field audiometry was used in concert with behavioral testing (ie, conditioned play, behavioral observation, and visual reinforcement) to measure response thresholds at frequencies of 500, 1000, 2000, and 4000 Hz and the mean sound field threshold noted.
RNA Isolation and Quantitative Polymerase Chain Reaction
RNA was isolated from middle ear biopsy specimens using TRIzol according to the manufacturer's instructions (Thermo Fisher Scientific). Spectrophotometry was performed to assess RNA purity and concentration, and RNA was stored at −80°C until use. A total of 150 ng of RNA extracted from middle ear biopsy specimens and commercially obtained trachea RNA (reference sample; Clontech/Takara) were reverse transcribed using Superscript VILO (Thermo Fisher Scientific) per the manufacturer's instructions. Expression of mucins, AQP5, and hypoxanthine phosphoribosyltransferase 1 (HPRT1 [OMIM 308000]; internal control/housekeeping gene) was examined using TaqMan assays. Amplification was performed on the Applied Biosystems ViiA7 (Thermo Fisher Scientific) at 52°C for 2 minutes, 95°C for 10 minutes, and 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. Reactions were performed in triplicate. Gene expression across multiple plates was normalized to the reference sample, then to the internal control/ housekeeping gene. Relative expression differences were determined using the 2 -ΔΔCT method. 21 
Analysis of Middle Ear Epithelial Thickness and Neutrophil Infiltration
After transport to the laboratory in HBSS, one middle ear biopsy specimen was embedded in Tissue-Tek OCT Compound (Sakura Finetek), placed on dry ice, and held at −80°C until use or cryosectioned to 6 μm. Sections were mounted on glass slides and stained with hematoxylin-eosin with use of an automated stainer. Slides were scanned at a magnification of ×400 (Nanozoomer; Hamamatsu Photonics). Images were analyzed by a board-certified pathologist (A.M.) using NDP.view2 software (Hamamatsu Photonics). Mean values from up to 13 distinct regions of tissue per patient were used as a representative sample of the middle ear. Areas in which the epithelium was detached or disrupted or areas with underlying specialized structures were not analyzed. Epithelial thickness in the number of cells was measured and recorded as a range (0-1, 2-5, and ≥5 cells) and/or assessed by the software (in micrometers) and verified by a micrometer. Percentage of neutrophil infiltrate was measured similarly across the tissue and recorded as present (1%-10%) or absent (0%).
Viscometry
Middle ear effusion samples (0.4-1.5 mL) were analyzed using a Kinexus Pro rheometer (Malvern). For mucoid effusions that required saline for suction, rheometry was performed exclusively on the mucoid portion of the specimen. All samples were prepared and tested in triplicate, and the reduced specific viscosity (ie, viscosity divided by specimen weight per volume) was calculated.
Statistical Analysis
The primary analytic approach was generalized linear regression modeling. Specifically, a gaussian linear regression was used to examine the effect of gene expression on continuous measures, such as hearing thresholds, epithelial thickness, and viscosity, as well as for comparing the gene expression between patient groups. A logistic regression model was used for the presence of neutrophil infiltration and a proportional odds logistic regression model for the categorized epithelial thickness measurement. We adjusted for correlation attributable to inclusion of measurements from both ears in a person by using generalized estimating equations with an independence working covariance structure and used robust sandwich estimators for the SE. All results are presented with 95% CIs. All analyses were conducted using SAS statistical software, version 9.4 (SAS Institute Inc).
Results
Patient Demographic Characteristics and Association of Gene Expression With Diagnosis
No significant difference in age, race, or sex representation was observed in OME relative to controls ( Table 1) . Although all patients with OME were recruited from the Children's Hospital of Wisconsin, only one control with cochlear implants was recruited in Wisconsin. The remainder were recruited from Sick Kids Hospital in Toronto because of higher patient volume. Although strict criteria were used to identify patients with OME, the overlap of OME and recurrent acute OM is an unalterable confounding issue in all studies of OM; 6 patients with OME also had recurrent acute OM (≥3 acute ear infections in 6 months). Expression of GFMs and AQP5 was elevated in patients with OME relative to controls ( Table 2) .
Hearing Loss Association With Gene Expression
Of the 24 patients with OME, 15 underwent pure-tone audiometry; data were obtained from both ears of all patients but one. Eight patients with OME underwent sound field audiometry. Audiometry data could not be obtained from one patient; this patient was not excluded from the study (gene expression, effusion viscosity, and middle ear epithelial thickness data were used from this patient). Correlation of mucin and AQP5 gene expression with hearing loss was evaluated. Strong correlation of only middle ear MUC5B (OMIM 600770) gene expression was observed with hearing loss (air-bone gap and sound field threshold) ( Table 3) . Measures reported in Table 3 are the estimated effects of a 2-fold increase in the gene expression on the outcome variable. As reported in Table 3 , if MUC5B expression doubled, the mean air-bone gap increased by a mean of 7.45 dB (95% CI, 2.65-12.24 dB) and sound field threshold increased by a mean of 6.66 dB (95% CI, 6.63-6.69 dB).
Middle Ear Epithelial Thickness and Neutrophil Infiltrate Association With Gene Expression
Mucin and AQP5 gene expression were also evaluated with respect to middle ear epithelial thickness in micrometers and neutrophil infiltration as a measure of inflammation and middle ear epithelial thickness in cell number as a measure of dysplasia. Middle ear MUC5B expression correlated with middle ear thickness in micrometers; as reported in Table 3 , when MUC5B expression doubled, the middle ear epithelial thickness increased by 3.54 μm (95% CI, 1.96-5.13 μm). Representative histopathologic images of OME and control specimens are displayed in the Figure. In the OME specimen (Figure, A) , nuclei Abbreviation: OME, otitis media with effusion. a Difference in mean (age) or risk ratio (sex, race) between controls and patients with OME. are enlarged and rounded, partially overlap, and contain coarse, granular chromatin. In many places, the epithelium is detached from the underlying stroma, and the epithelial cells are discohesive in places. The stroma is looser and less dense than the stroma of controls (Figure, B) . A dense, widespread inflammatory infiltrate composed of plasma cells, lymphocytes, and polymorphonuclear cells is present, consistent with the clinical diagnosis of acute OM. In contrast to the OME specimen, the control specimen demonstrates compact, cohesive epithelium approximately a mean of 2 cells thick. The epithelial cells are flat to oval with abundant cytoplasm and nonoverlapping, elongated, small, flattened nuclei arranged in a parallel, organized pattern. The subepithelial stroma is dense and paucicellular. Most of the vascular spaces in the stroma are full of normal-appearing red blood cells. Inflammatory cells are inconspicuous throughout the specimen. Middle ear MUC5B expression also correlated with middle ear epithelial thickness in cell number and neutrophil infiltration of the mucosa; as reported in Table 4 , doubled MUC5B expression was associated with a 1.79-fold greater odds (95% CI, 1.04-3.07) of being in a higher category of middle ear epithelial thickness in cell number and 1.70-fold greater odds (95% CI, 1.07-2.72) of neutrophil infiltration.
Gel-Forming Mucins and Aquaporin Gene Expression in Hearing Problems
Effusion Viscosity Association With Gene Expression
An association of MUC5B gene expression was observed with effusion viscosity as evaluated by rheometry (Table 3) . Similarly, an association was observed between AQP5 gene expression and effusion viscosity (Table 3) .
Discussion
Many potential health difficulties are associated with OME, including infectious complications, the development of cholesteatoma, and the need for surgical interventions, which are sometimes complex and have their own attendant risks. However, one of the most important deleterious effects of OME is the potential for OME and associated hearing loss. Otitis media with effusion is the most common cause of hearing loss in children and has important developmental consequences in children if left untreated. [1] [2] [3] [4] Little research has been conducted to investigate the specific molecular and pathologic events in the middle ear that lead to hearing loss despite the potential that manipulation of such events holds for ameliorating the consequences of OME. Furthermore, a clear need has arisen for biomarkers to identify patients who may be particularly susceptible to OME-attributed hearing loss and may benefit from early intervention. 22 To our knowledge, this study is the first to link phenotypic characteristics, such as patient hearing levels, middle ear inflammation, and middle ear fluid viscosity, to expression of mucin genes, which have been demonstrated in our and other laboratories to be hypersecreted during OME and a cause of OME pathophysiologic findings. Although the results of our study warrant validation in a larger population, this data set provides a number of important correlative observations that may provide avenues of future investigation into individualized assessment of patient characteristics for a personalized approach to OM. Consistent with previous reports, 8, 19, 20 this data set demonstrates elevated expression of MUC2 (OMIM 158370), MUC5AC (OMIM 158373), and MUC5B genes in the middle ears of patients with OME relative to a control population without OM. The analysis of mucin correlation with OME disease metrics reported herein is the first, to our knowledge, to demonstrate that, of these mucins, only MUC5B expression is Abbreviations: AQP5, aquaporin 5; MUC2, mucin 2; MUC5AC, mucin 5AC; MUC5B, mucin 5B; OME, otitis media with effusion. Abbreviations: AQP5, aquaporin 5; MUC2, mucin 2; MUC5AC, mucin 5AC; MUC5B, mucin 5B. a Ranging from 0 to 5, with 0 indicating absent; 1, thin serous; 2, thick serous; 3, mucoid; 4, thick mucoid; and 5, extremely thick mucoid. Score was determined by the surgeon as described in the Study Participants subsection of Methods.
significantly associated with effusion viscosity, neutrophil infiltration, middle ear mucosal inflammation and hyperplasia, and hearing loss. The association of MUC5B with OME pathophysiologic findings is in accordance with its expression during chronic airway disease. Although MUC5AC predominates in the healthy lung, MUC5B is the predominant mucin in cystic fibrosis and chronic obstructive pulmonary disease. 23, 24 Similarly, MUC5B is the predominant mucin in middle ear effusion and mucosa during OME. 8, 25, 26 Prolonged stimulation is required for MUC5B expression relative to other mucins in in vitro models of OM, 9,10 further supporting its role as a chronic response gene in the middle ear. The association of MUC5B expression with viscous, difficult-to-clear effusion, chronic disease, and concomitant hearing loss is additionally supported by its biochemical properties. MUC5B is the largest and potentially the most viscous mucin: it hosts the longest repeat or glycosylation region of any mucin in the largest exon found in any vertebrate gene and, given its numerous cysteine residues, bears the capacity to oligomerize at both ends of the molecule via degradation-resistant disulfide bonds. 8, 26, 27 Effusion viscosity in OM has previously been associated with 2 primary determinants: glycoproteins and DNA. 7 MUC5B is not only the predominant glycoprotein in middle ear effusion but also has previously been found to be associated with neutrophil extracellular traps, the predominant innate immune response during OME. 25, 28 Accordingly, in our study, MUC5B was associated with increased neutrophil infiltration. Neutrophil extracellular traps are incorporated into bacterial biofilms, 29, 30 and neutrophil extracellular trap mediators, such as neutrophil elastase and metabolites from the biofilm, perpetuate inflammation and sustain epithelial mucin hypersecretions, 31 thereby generating a feedback loop that reduces likelihood of effusion clearance and results in chronic illness. These data are also the first, to our knowledge, to demonstrate elevation of the level of AQP5 in a clinical population with OME and its correlation with effusion viscosity. Similar to GFMs in the middle ear during OM, AQP5 expression in the lung is responsive to tumor necrosis factor and lipopolysaccharide. 32, 33 Posttranscriptional mechanisms that control gating and subcellular localization are important regulators of AQP function, and lipopolysaccharide also stimulates translocation of intracellular AQP5 to the plasma membrane in airway cells. 34 On expression in the lung, AQP5 promotes airway MUC5AC and MUC5B expression. 17, 18, 35 In this study, levels of MUC5B and AQP5 expression were elevated in patients with OME relative to controls, suggesting that similar regulatory mechanisms for AQP5 and GFM expression may exist in the middle ear during OM. Aside from its role in mucin regulation, AQP5 serves other key functions in innate immunity and maintenance of epithelial barrier integrity. AQP5 promotes airway epithelial expression of an adhesion molecule (intercellular adhesion molecule) and chemokine (lipopolysaccharide-induced CXC) secretion essential for neutrophil recruitment; accordingly, Aqp5 −/− mice exposed to cigarette smoke have reduced alveolar neutrophil recruitment and protection from lung damage relative to wild-type controls. 36 AQP5 also directly interacts with microtubules in epithelial cells to influence paracellular permeability independently of water transport. 37 Additional work in in vitro and in vivo models will be required to determine the requirement of AQP5 for GFM expression and accumulation of effusion in the middle ear and the overall contribution of AQP5 to the disease process of OME. Given the findings from our study, a logical next step will be to follow up patients in a prospective manner to assess the potential correlation of MUC5B expression with the likelihood of ongoing difficulties, such as disease recurrence and additional operations to determine whether these patients represent a group who may benefit from closer follow-up or earlier intervention. To this end, our laboratory has already initiated work to bring the findings of the current study to the threshold of a personalized approach to patients with OME through analysis of genetic responses, inflammation, and associated morbidity with hearing loss. An additional related avenue for investigation is identification of specific genetic characteristics, such as MUC5B polymorphisms, that may influence patient susceptibility to OME or efficacy of treatment, similar to the association that our laboratory identified between a long MUC5AC allele and recurrent OM. 38 
Limitations
A limitation of this study is the difference in demographic characteristics and geographic origin of patients with OME and controls. Genes that control the immune response to infection are highly polymorphic and subject to confounding by population stratification, presenting a limitation that should be considered when interpreting candidate gene associations without family member controls. [39] [40] [41] As noted in the Methods section, the current study had a natural history and natural care pattern design; patients were referrals treated in a routine practice setting rather than screened and followed up from initial enrollment. Strict criteria were used when considering patients for surgery as noted; however, given the natural care pattern design, there were inherent limitations, for example, in knowing the exact pattern or length of effusion. However, inasmuch as the study participants met a consistent definition for OME, the design provides the best ability to eventually generalize the findings more broadly in the future to clinical practice; rather than generating an artificial construct irreproducible in clinical practice, the design facilitates investigation of significant differences in a setting that mirrors that of clinical practice. The statistically significant results observed with such design may be considered to be highly substantive for future work and consideration. 22, 41 Additional limitations include differences in the method of fixation of specimens for histopathologic analysis that were obtained from Canada relative to the United States. The potential for such differences to influence outcomes was mitigated by assessing the epithelial thickness in micrometers and cell count. The latter is not affected by potential tissue shrinkage during fixation and corroborated the difference between groups that was observed in thickness in micrometers. Last, specimens were collected from patients with unilateral and bilateral effusion. Although we were able to detect phenotypic differences in OME relative to controls, the OME phenotype may have been stronger in a population with exclusively bilateral effusion. This is an important question directed at the interface of genotypic characteristics, phenotypic characteristics, and environmental characteristics that drive disease expression, for which we have proposed future work in a larger trial.
Conclusions
To our knowledge, these data are the first to show association of expression of a specific mucin with inflammation, effusion viscosity, and hearing loss during OM and the first to demonstrate elevation of AQP5 levels during OM and its association with effusion viscosity. Although additional work is required to validate causation, our findings implicate MUC5B in OME-associated hearing loss and suggest that MUC5B-targeted treatment strategies may be beneficial for treatment of OME.
